Clinical Trials
9 trialsNCT02386826 2023-09-21
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01911507 2021-10-13
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT01324479 2020-12-19
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01546428 2020-12-19
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02925104 2020-12-19
A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Novartis
Phase 1 Completed
NCT02474537 2020-12-10
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Novartis
Phase 1 Completed
NCT02520752 2020-12-10
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02626234 2020-12-10
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01072266 2017-11-22
A Dose-escalation Study in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1 Completed